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Abstract
Endothelial progenitor cells are increasingly being studied in various diseases ranging from ischemia, diabetic
retinopathy, and in cancer. The discovery that these cells can be mobilized from their bone marrow niche to sites
of inflammation and tumor to induce neovasculogenesis has afforded a novel opportunity to understand the tissue
microenvironment and specific cell-cell interactive pathways. This review provides a comprehensive up-to-date
understanding of the physiological function and therapeutic utility of these cells. The emphasis is on the systemic
factors that modulate their differentiation/mobilization and survival and presents the challenges of its potential
therapeutic clinical utility as a diagnostic and prognostic reagent.
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Introduction
As a new decade of cancer research begins, many of the
same problems in investigating tumor growth and metas-
tasis remain. Much of the difficulty is due to the heteroge-
neity of not only the tumor types, but the cellular
environment of the individual tumors themselves. All can-
cers though still go through specific initiation, promotion,
and progression phases. The initiation events are varied
from endogenous metabolites to exogenous insults while
the tumor microenvironment in part dictates the promo-
tion and progression phases. The unanswered questions of
why some tumors remain benign while others become
malignant, why some only grow at their primary foci while
others rapidly metastasize, and why some are susceptible
to chemotherapeutics while others remain resistant is still
an enigma. These differences have lead researchers to
develop new strategies of cancer treatment aimed at the
body’s normal physiological processes that tumors are able
to manipulate to their own end.
One recent strategy that has emerged in cancer
research involves targeting of tumor associated blood
vessels which provide growing tumors with oxygenated
blood and growth factors necessary for maintenance and
metastasis. The uncontrolled growth of tumors leads to
formation of a hypoxic tumor microenvironment leading
to a proangiogenic signalling cascade. Initial work was
focused on tumor induced angiogenesis, or sprouting of
existing vasculature toward the tumor. However, recent
research has identified a novel mechanism in vasculature
development known as vasculogenesis, or the formation
of new vessels from bone marrow derived progenitor
cells rather than sprouting or elongation of existing ves-
sels. Neovasculogenesis is due, in part, to bone marrow-
derived endothelial progenitor cells (BM-EPCs) which
are released from the marrow and home to sites of
blood vessel formation.
While the rapid expansion of cells leads to activation of
neovascularization, the process relies on the formation of
a hypoxic, and thus inflammatory, tumor microenviron-
ment that signals not only for progenitor but also immu-
nomodulatory cell migration. Secretion of proangiogenic
as well as both pro and anti-inflammatory cytokines by
these modulating cells also influences the genetic and
phenotypic characteristics of tumor cells. Such cytokines
include IL-1 and TGF-b which lead to an epithelial to
mesenchymal transition (EMT) during which tumor cells
downregulate epithelial markers including E-cadherin
and upregulate mesenchymal markers as well as tran-
scription factors like SNAIL and TWIST increasing their
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metastatic propensity [1-3]. Inflammation, also induced
by cytokines secreted by infiltrating macrophages, alters
the tumor cell epigenome and modulation of proangio-
genic proteins [4]. Tumor cell development is compar-
able to a “wound” that never heals in which a steady
inflammatory environment is propagated. Future work
must also be directed toward the influx of immunomodu-
lating cells and their cytokine profile.
We however have identified another mechanism of
BM-EPC induced vasculogenesis, in which progenitor
cells contribute to the development of breast tumor ves-
sel formation in an estrogen dependent manner [5].
Indeed, clinically circulating EPCs are being correlated
with increased tumor growth and since they home to
tumor sites are being targeted as potential Trojan Horses
for specific gene therapy delivery [6]. Identification of
this novel cell type’s role in neovasculogenesis may pro-
vide researchers a common target for anti-tumor therapy
directed against the tumor and the tumor microenviron-
ment. This review, while focusing on the difference
between angiogenesis and vasculogenesis, the characteris-
tics of the bone marrow derived progenitor cells that
contribute to neovasculogenesis, and the factors that
modulate them, places the process of neovasculogenesis
as a necessary modulator of the tumor microenvironment
capable of promoting a subset of tumor cells which are
responsible for tumor progression.
Angiogenesis vs. Vasculogenesis
Angiogenesis is the formation of new vessels from existing
vasculature by two distinct methods termed sprouting and
non-sprouting angiogenesis. Sprouting angiogenesis (SA)
occurs when endothelial cells migrate and divide off the
existing vessels and fusion of vacuoles within the endothe-
lial cells creates the vascular lumen [7]. Migration of these
cells relies on a source of proangiogenic stimuli as well as
proteases that degrade the basement membrane which
allows mobilization and proliferation of endothelial cells
that later form sprouts. Non-sprouting angiogenesis, or
intussesceptive angiogenesis (IA), occurs via splitting of an
already existing vessel into two by formation of transcapil-
lary pillars followed by vascular myogenesis, although the
exact mechanism is poorly understood [7]. Angiogenesis is
necessary during embryonic development but also plays
important roles throughout postnatal life in wound heal-
ing, tissue ischemia, and tumor vasculature formation and
is now a major therapeutic target in cancer treatment.
However, recent studies have shown that a mechanism
different from angiogenesis exists for formation of vessels
in adults called postnatal vasculogenesis or neovasculari-
zation. During vasculogenesis precursor cells from adult
bone marrow are mobilized into circulation in response
to various signals and home to the source where they dif-
ferentiate into mature endothelial cells, assisting in the
ongoing vascular development [8]. Neovascularization is
a critical process for revascularization of ischemic tissues
and wound healing but plays a role pathologically as it
can be induced by cancers to aid in tumor growth and
metastasis, and can also be seen in conditions like dia-
betic retinopathy and retinopathy of prematurity [8]. The
bone marrow precursor cells that aid in neovasculariza-
tion are known as endothelial progenitor cells.
EPCs: Physiological and Biological Functions
Endothelial progenitor cells (EPCs) are bone marrow
derived cells that can be found in the peripheral and umbi-
lical cord blood and were first isolated using magnetic
micro beads by Asahara [9]. Studies have shown that the
term ‘EPCs’ cannot be used to define a single cell type but
rather should be used to refer to multiple cell types cap-
able of differentiating into the endothelial lineage [10].
First, they are considered derivatives of hemangioblasts
and express CD34, VEGFR-2 and CD133 on their surface
(Table 1). CD133, a transmembrane, 120 kDa glycopro-
tein, is expressed by EPCs but not by mature endothelial
cells. These adult EPCs and the embryonic angioblasts
share similar characteristics as both are derived from the
hemangioblast precursors and both have the capacity to
home to the periphery where they proliferate and differ-
entiate into mature endothelial cells. Second, EPCs are
considered one subset of cells derived from bone marrow
multipotent adult progenitor cells (MAPCs). MAPCs also
express CD133 and VEGFR-2 but lack CD34 or vascular
endothelial cadherin expression [10]. In vitro experiments
on MAPCs have shown that they differentiate into mature
endothelial cells when grown in a serum-free media with
VEGF (Table 1). Lastly, the myelo/monocytic cells, also
derived from the bone marrow, can differentiate into EPCs
[10]. The myelo/monocytic cells express CD14 on their
surface and form mature endothelial cells positive for
vWF, VEGFR-2, and CD45 (common leukocyte antigen)
expression when cultured (Table 1). Irrespective of their
origin, EPCs in general have the functional ability to take
up acetylated LDL, and bind to Ulex europaeus agglutinin
1 (UEA1) [11]. Hence, in vivo three groups of progenitors
have been found to differentiate into mature endothelial
cells, the hemangioblasts, the MAPCs and the myelo/
monocytic cells. Two groups of EPCs have been defined in
in vitro models, the early EPCs, which are derived from
the monocytes and have surface expression of CD45,
CD14, CD11b and CD11c, and the late EPCs, which are
believed to be a subset of CD14- CD34- KDR-(kinase insert
domain protein receptor) cells that do not express CD45
or CD14 [12].
Studies of EPC modulation and function require their
isolation and expansion. EPCs are obtained from ex vivo/
in vitro culture of unfractionated peripheral blood mono-
nuclear cells (MNCs) or by direct flushing of bone marrow
George et al. Journal of Hematology & Oncology 2011, 4:24
http://www.jhoonline.org/content/4/1/24
Page 2 of 8
and expansion in endothelial specific media. Only two dif-
ferent cell types have been isolated from the cultures so
far, the endothelial cell-like cells (EC-like cells), and the
endothelial outgrowth cells (EOCs). These two cell types
have few similarities; they can effect neovascularization in
vivo, take up LDL by binding UEA-1 lectin and have simi-
lar surface markers such as CD31, vWF [13,14]. However,
the EC-like cells are derived from CD45+ hematopoietic
lineage cells, they are spindle shaped and are generated
after 4-21 days in culture, they have a low proliferative
potential and do not produce vascular tubes in vitro.
In vivo they have myeloid progenitor cell activity and dif-
ferentiate into macrophages but they do not form vessels
[13,14]. Although they are unable to form vessels directly,
they have an indirect paracrine effect on angiogenesis by
secreting angiogenic factors locally. Hence, these cells are
not considered true EPCs but can be referred to as ‘Angio-
genic cells’ [13]. The EOCs, unlike the EC-like cells, origi-
nate from CD45- CD133- CD34+ cells and do not have
hematopoietic surface markers. EOCs express CD31,
CD34, CD105, CD146, VE-Cadherin, and VEGFR-2 on
their surface. In cultures they are polygonal cells and
appear after 7 days, they are highly proliferative, and they
do not differentiate into hematopoietic cells. The EOCs
can form vessels both in vitro and in vivo [13].
To aid in neovasculogenesis, EPCs mobilize from the
bone marrow in response to endogenous or exogenous
signals and home to peripheral tissue sites. Their surface
receptor P-selectin glycoprotein ligand-1(PSGL-1) inter-
acts with P-selectin and E-selectin expressed on endothe-
lial cells, followed by autocrine and paracrine activation
of EPCs resulting in differentiation or transdifferentia-
tion, proliferation and vascular growth [12]. b 2 integrins
(LFA-1, Mac-1) and b 1 integrin also mediate homing of
the EPCs to the periphery and b 2 integrin helps in the
arrest and migration of EPCs across the endothelial cells
[15]. The physiological function of circulating EPCs is to
maintain vascular integrity which is also crucial in the
pathogenesis of various diseases with vascular insult. The
vasculogenic potential of EPCs is also exploited by
tumors by recruiting EPCs to facilitate their growth and
metastasis [12].
EPCs are not only involved in physiological neovascu-
larization but also involved in wound healing, tissue
regeneration in ischemia (e.g. myocardial ischemia, limb
ischemia), tissue remodelling (Diabetes mellitus and
Heart failure) and neovascularization and growth of
tumors [16]. EPCs are mobilized from the bone marrow
in response to paracrine signals generated by ischemic
tissue and tumor cells including GM-CSF and VEGF,
which play a critical role in mobilization of EPCs to
ischemic tissues and tumors. Hypoxia in tumors and
ischemic tissues mediate EPC recruitment by activation
of HIF-1 which leads to increased synthesis of a potent
angiogenic factor VEGF. Also growing tumors secrete a
number of other factors like fibroblast growth factor
(FGF), SDF-1, osteopontin, CCL2 and CCL5 which help
in EPC mobilization [17]. EPCs are then released into cir-
culation by activation of MMP-9 which degrades the
extracellular matrix and transforms membrane-crossing
Kit ligand (mKitL) to solubility Kit ligand (sKitL) in the
bone marrow [18,19] (Figure 1). The physiological func-
tion of circulating EPCs is to maintain vascular integrity
which is also crucial in the pathogenesis of various dis-
eases with vascular insult. The vasculogenic potential of
EPCs is also exploited by tumors by recruiting EPCs to
facilitate their growth and metastasis [12]. The tumor
microenvironment plays a major role in activating circu-
lating EPCs and mediating neovascularization and stres-
sors in the tumor microenvironment such as hypoxia,
Table 1 Cell surface markers that functionally define EPCs
Surface Markers Function Cell Expression
CD34 Glycoprotein important for cell-cell adhesion, maintenance of
stem cells in bonemarrow, mediates attachment of leukocytes
to high endothelial venules [57]
Hemangioblasts, Endothelial Progenitor Cells, Vascular
Endothelial Cells [10]
VEGFR-1 (Flt1) Tyrosine kinase receptor for VEGF A and B, important for
endothelial cell assembly into vessels [58]
MAPC, Myelo/Monocytic Progenitors, Vascular Endothelial
Cells [58]
VEGFR-2 (Flk1, KDR) Tyrosine kinase receptor for VEGF A,C,D,&E, critical for
hematopoietic and endothelial cell development, principal
mediator of VEGF-A mitogenic and pro-migration ability [59]
Hemangioblasts, Endothelial Progenitor Cells, MAPC,
Myelo/Monocytic Cells, Vascular Endothelial Cells,
Lymphatic Endothelial Cells [10]
CD133 (Prominin 1) Membrane glycoprotein, function unknown, serves as a marker
for hematopoietic and endothelial progenitor cells [60]
Hematopoietic Cells, Endothelial Progenitor Cells [10]
CD45 Protein tyrosine phosphatase, important for lymphocyte
activation via LCK and FYN [61]
Cells of Hematopoietic System [61]
VE-cadherin Calcium dependent glycoprotein, intercellular junction protein
necessary for proper vascular development [62]
Mature Endothelial Cells [62]
vWF Secreted glycoprotein important for platelet aggregation [63] Produced by Endothelial Cells and Megakaryocytes, Stored
in Platelets [10,63]
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glucose deprivation, and reactive oxygen species upregu-
late transcription of angiogenic factors like VEGF, SDF-1,
MCP-1, and erythropoietin in EPCs [12,20,21]. Also
CCL11 mediates tumor angiogenesis by recruitment and
activation of eosinophils which secrete angiogenic factors
[22].
Tumor growth has an avascular and vascular phase,
and it is in the avascular phase of tumor growth and
ischemic tissue that hypoxia induced EPC mobilization
is active [20,21]. The EPCs recruited to the tumor or
ischemic sites have a direct structural function by form-
ing the vessel or an indirect paracrine effect by secreting
angiogenic factors. The role of EPCs in tumor neovascu-
larization was studied in an Id1 +/- Id3-/- mouse model
which is tumor resistant and has defective angiogenesis,
where transplantation of wild type bone marrow to the
mutant mice restored tumor angiogenesis and growth.
In the same study they also found that both VEGFR1
and VEGFR2 are required for tumor growth and block-
ing these receptors together completely abolishes tumor
growth [23]. Mobilization and incorporation of EPCs in
tumor vessels varies with the tumor type, tumor stage
and tumor treatment. Studies on different types of
tumors and EPCs have shown an increase in the circu-
lating EPC population in lymphomas, leukemia, hepato-
cellular carcinoma, and colon cancer. Because of this
EPCs have a diagnostic, therapeutic and prognostic
potential in cancers. EPCs can thus act as biomarkers of
tumor development and/or progression and can be stu-
died by injection of labelled AC133+ cells and tracking
it with MRI. EPCs are known to home to tumor tissues,
and this property allows their use as a therapeutic deliv-
ery vehicle in combination with targeted anti-angiogenic
or cytotoxic effects. EPCs are also used as gene delivery
vehicles to tumor tissues [20,24]. The physiological sig-
nificance of EPCs is varied and is of relevance in both
normal and tumor tissue regeneration. Clinical exploita-
tion of these cells is critically dependent on the biology


























Figure 1 Trafficking of EPCs to ischemic/tumor tissues as directed by major cytokine/chemokine expression. Endothelial progenitor cell
homing from the bone marrow niche to sites of neovasculogenesis is dependent a cytokine/chemokine gradient. The cellular stress induced by
ischemic and tumor tissue leads to the release of a number of pro-angiogenic factors, including VEGF. VEGF stimulation of stromal cells leads to
an increase in eNOS and NO production, leading to MMP-9 secretion. MMP-9 then converts m-KitL to s-KitL aiding in the release of EPCs from
bone marrow stromal cells. The EPCs then migrate toward the angiogenic gradient via chemokine receptors including CXCR-4 and VEGFR-2.
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Modulation of EPC Functions
EPC homing relies on creation of a gradient of endogen-
ous proteins. One of the best studied is vascular
endothelial growth factor (VEGF), a homodimeric glyco-
protein with a molecular weight of 45 kDa which is
synthesized by normal cells and upregulated by hypoxia.
VEGF is not only secreted locally where it has paracrine
like effects but is also secreted into circulation and acts
as a hormone [25]. Under hypoxic conditions transcrip-
tion factors like Hypoxia Inducible Factor - 1 (HIF-1)
are activated leading to increased transcription of VEGF
[24]. VEGF stimulates VEGFR1 and VEGFR2 receptors
present on endothelial and hematopoietic stem cells and
activates matrix metalloproteinase - 9 (MMP-9) which
in turn cleaves and activates Kit ligand (KitL) and
induces proliferation and migration of EPCs and hema-
topoietic cells [26].
The proangiogenic protein angiogenin also plays a role
in EPC function. Angiogenin is a 14-kDa protein that
binds and activates endothelial cells leading to prolifera-
tion and migration and has ribonucleolytic activity.
Angiogenin also translocates to the nucleus of cells,
which is necessary for other proteins, including VEGF, to
exert their proangiogenic effects [27]. Angiogenin may
bind with follistatin, another angiogenic protein that in
an in vivo model was found to increase the number of
tumor associated capillaries but not tumor size [28,29].
Another family of angiogenic factors is the Angiopoie-
tins (Ang-1, 2), 57 kDa proteins that regulate both neo-
plastic and non neoplastic neovasculogenesis in the
embryo and post natal life and mitigate their effects by
binding cognate tyrosine kinase receptors (Tie-1 and Tie-
2). Ang-1 can activate the receptor Tie-2 and lead to
downstream activation of the phosphatidylinositol 3’-
kinase/Akt prosurvival pathway in endothelial cells. In vivo
however, studies on Ang-1 have showed that over expres-
sion of Ang-1 in tumors decreases tumor neovasculariza-
tion and tumor size [30]. The function of Ang-2 still
remains controversial, as early models suggested Ang-2
was a functional antagonist of Ang-1, however, a role of
Ang-2 in vessel sprouting has been identified [31,32].
Cytokines also promote EPC mobilization to the per-
iphery. Granulocyte-colony stimulating factor (G-CSF)
and granulocyte monocyte-colony stimulating factor
(GM-CSF) are glycoproteins which stimulate production
of granulocytes in the bone marrow, and also influence
the proliferation, differentiation, and migration of bone
marrow EPCs [33]. Another cytokine that may play a role
in EPC modulation includes IL-8. Binding of IL-8 to
human umbilical vein endothelial cells (HUVECs) that
express the receptors CXCR1 and CXCR2 lead to
endothelial cell proliferation and capillary tube formation
in vitro [34]. Further, in acute myocardial infarction, IL-8
was associated with an increase in circulating CD133+
cells [35]. Taken together with the fact that breast cancer
patients in higher stages had significantly more IL-8
mRNA may shed light on a novel role of IL-8 on progeni-
tor cell mediated neovascularization [36].
Chemokines and their receptors are involved in EPC
migration and differentiation as well. CCR2 is a chemo-
kine receptor expressed on the surface of EPCs and vascu-
lar smooth muscle cells (VSMCs) that mediates
chemotaxis to areas of endothelial denudation, which
secrete monocyte chemoattractant protein-1 (MCP-1/
CCL2), leading to angiogenesis [37]. EPCs also express
another chemokine receptor CCR5 which binds its ligand
RANTES/CCL5 and plays an important role in atherogen-
esis and vascular remodelling [37]. CXCL12 or stromal
cell derived factor - 1a (SDF-1a) is another chemokine
responsible for EPC mobilization and also recruitment
along hypoxic gradients via the CXCR4 receptor. During
tumor growth, hypoxic regions stimulate the transcription
factor hypoxia inducible factor 1 (HIF-1) leading to tran-
scription of proangiogenic proteins including VEGF and
SDF-1a [38]. Formation of the SDF-1a gradient leads to
mobilization of EPCs. Further, chemotaxis of EPCs toward
SDF-1a is increased by IL-3 and EPCs derived from the
bone marrow respond better than those isolated from cir-
culation [39]. The chemokine eotaxin or CCL11 mediates
angiogenesis either directly via the CCR3 receptor of
human microvascular endothelial cells or indirectly by
recruitment and activation of eosinophils which release
angiogenic factors like transforming growth factor a and b
(TGF-a, TGF-b) [22]. Chemokine CXCL1 and its receptor
CXCR2 are involved in endothelial repair after injury.
Recently, activated platelets have been implicated in EPC
recruitment and migration via release of b-thromboglobu-
lin, a precursor CXCL12 and CXCL7 [15].
Recent studies involving endothelial nitric oxide
synthase have showed that nitric oxide (NO) plays an
important role in angiogenesis involving mature endothe-
lial cells and neovasculogenesis involving EPCs [40]. In
models of mice deficient in endothelial nitric oxide
synthase (NOS3-/-), VEGF stimulation of EPC mobiliza-
tion was reduced and only intravenous infusion of wild
type progenitor cells, not bone marrow transplantation,
resulted in restoration of neovascularization, demonstrat-
ing the role of nitric oxide in mobilization of progenitor
cells into circulation [41]. In rat bone marrow ex vivo
models, administration of angiotensin II lead to eNOS
dependent NO production in EPCs and modulated EPC
adhesion and apoptosis [42].
Exogenous factors, including drugs like Statins and
Thiazolidinediones are also involved in EPC migration and
proliferation. Statins are drugs which inhibit the enzyme
3-hydroxy-3-methylglutryl coenzyme A (HMG-CoA)
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involved in cholesterol biosynthesis. They also activate
both endothelial progenitor cells and mature endothelial
cells by stimulation of the Akt signalling pathway [43].
Endogenous factors used therapeutically like G-CSF and
GM-CSF, used to treat haematological diseases, are known
to induce BM-EPCs mobilization and migration and may
present further complications. The factors listed above uti-
lize prosurvival chemokine/cytokine mediators for cellular
modulation. We and others discovered the presence of
estrogen receptor in EPCs suggesting a novel role of the
E2-ER pathway in the survival and biological activities of
EPCs.
Role of ER on EPC neovascularization
Epidemiological observations have indicated a role of hor-
mones, specifically estrogen, in vascular repair and mainte-
nance. Such observations include a comparative decrease
of heart disease and increase in vascular repair in women
compared to men. Initial work focused on the role of
estrogen in ischemic tissue and heart models found that
estrogen is indeed cardio protective and aids in vascular
repair. One such mechanism is via upregulation of prosta-
cyclin in endothelial cells leading to vasodilation and inhi-
biting platelet aggregation [44,45]. In vivo studies using
estrogen receptor a and b knockout mice have verified
that estrogen and its receptors are important specifically
in EPC dependent neovascularization of ischemic tissue.
The activation of EPCs by estradiol is predominantly
mediated via ERa, and EPCs treated with estradiol showed
an increased expression of ERa mRNA transcripts.
Further, VEGF expression was increased in treated WT
EPCs whereas VEGF expression was minimal in ERa
knock out EPCs [46]. Estrogen activates EPCs via the
PI3K/Akt pathway, phosphotidlyinositol-3 kinase (PI3K)
converts PIP2 to PIP3, PIP3 in turn phosphorylates Akt
which is responsible for EPC migration and proliferation
[47]. Estrogen also increases the telomerase activity in
EPCs and prolongs their survival [48]. Interestingly, in
mice deficient for eNOS expression, estradiol has no effect
of EPC mobilization, indicating a major role of nitric oxide
in EPC function [49]. Estrogen also exerts effects on non-
ischemic EPC aided vascularization, for example previous
work observed a cyclical increase in EPC mobilization fol-
lowing a rise in estrogen and VEGF levels during men-
strual cycling in uterine tissue [50,51].
Recently, the role of estrogen in tumor induced neo-
vascularization has emerged lending focus to its ability
to significantly impact not only tumor growth and
development but also metastasis. Previously, our lab
observed an increase in BM-EPC mobilization and hom-
ing to tumor tissue in an in vivo transgenic mouse
breast tumor model when mice were supplemented with
a slow release estradiol pellet. This supplementation
lead not only to an increase in tumor vessel formation
but also an increase in mRNA transcripts of proangio-
genic genes including angiopoietins 1 and 2, MMPs 2
and 9, and VEGF [5]. Using transgenic animals in which
GFP was under control of the Tie2 (TEK) promoter, we
were able to visualize BM-EPC association with tumor
blood vessels. Further, in an in vitro model tumor cell
conditioned media from estradiol supplemented cells
also lead to BM-EPC tubulogenesis when compared to
control conditioned media [5]. Thus, hormones, in par-
ticular estrogen, play a large role in EPC function and
are pivotal in tumor development in hormone respon-
sive tissues. It is this novel mechanism of estrogen
mediated tumor progression that will be the aim of
future therapeutic strategies.
Potential for future work
While the major physiological role of circulating EPCs in
adults is to maintain vascular integrity, they can also home
to and aid in revascularization of ischemic and tumor tis-
sues [7]. Indeed previous clinical correlations have
reported an increase in EPC circulation in breast, ovarian
and pancreatic cancer patients with a positive correlation
to tumor stage and size [6,52,53]. It is this observation that
may prove EPC’s usefulness as a biomarker for early
tumor detection where EPCs serve as a sensor of tumor
initiation. Further, tagging of EPCs may allow tracing of
their mobilization and homing to tumor tissues aiding in
specific, targeted early detection of tumor growth, a critical
determinant of aggressive tumor growth outcome.
This targeted homing can be manipulated for future
therapeutic research. One such method may utilize
EPCs as gene delivery vehicles in the treatment of
tumors. Such a method would involve ex vivo expanded
EPCs that can be transduced with a transgene expres-
sing anti-angiogenic factors and administered to patients
directed at blocking tumor growth [54]. Drug delivery
vehicles currently used to deliver chemotherapeutic
drugs to the tumors are liposomes and exosomes, analo-
gous to these, EPCs can be used as a ‘Trojan horse’ for
targeted delivery of drugs to tumor tissues. Another
potential therapeutic strategy aimed at blocking EPC
mobilization and migration from the bone marrow itself
would also impact tumor growth and metastasis and
may increase efficacy of early detection and surgical
intervention [20].
While the methods described may prove EPCs as
powerful weapons against cancer development, their
role in other physiological functions also needs consid-
eration. EPCs have a possible therapeutic benefit in
ischemic diseases as injection of ex vivo expanded EPCs
into patients may have potential regenerative effects in
ischemic tissues opening the door to novel treatment
strategies for diabetes. EPCs may also be used to con-
struct endothelial coated vascular grafts which may have
George et al. Journal of Hematology & Oncology 2011, 4:24
http://www.jhoonline.org/content/4/1/24
Page 6 of 8
a better patency rate [55]. On the negative side increas-
ing the number of circulating EPCs to promote neovas-
culogenesis in ischemia should be investigated for
plaque destabilization and differentiation into athero-
genic cells which can cause embolism [56].
Conclusions
Endothelial Progenitor cells originate from the bone mar-
row and have the ability to differentiate into multiple cell
lines. Endogenous factors like VEGF, cytokines, estradiol,
and eNOS with exogenous factors like statins and thiazoli-
dinediones mediate recruitment of EPCs into the circula-
tion. Circulating EPCs have a wide array of functions in
tissue regeneration, tissue remodelling and cancer progres-
sion. In tumors and ischemic tissues EPCs have a direct
structural role of differentiating into mature endothelial
cells and an indirect paracrine effect by secreting angio-
genic factors. Hypoxia in ischemic tissues and during the
early phase of tumor growth is crucial for EPC recruit-
ment and is mediated via upregulation of HIF-1 leading to
an increase in the transcription of proangiogenic proteins
including VEGF. EPCs also play a major role in the patho-
genesis of heart failure, diabetes and vascular diseases with
studies showing that high circulating EPCs have a direct
correlation with decreased vascular complications. Further
research to study the biology of EPCs is essential and ulti-
mately will lead to the development and utilization of
EPCs as a powerful diagnostic, therapeutic and prognostic
tool in a wide variety of diseases.
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